- Function
- Main Sponsor
Main Sponsor
BeiGene, which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 11,000 colleagues spans six continents.
Visit BeiGene to learn more:
Learn more about BeiGene’s science and medicines
Explore BeiGene’s medical educational platform for healthcare professionals
BeiGene’s Oncology Pipeline
Pursuing Innovation on 3 Fronts
Immuno-Oncology Agents: Our research and development team focuses on precision targeting of immune checkpoints and other mechanisms of tumour-associated immunity to develop novel drug candidates that synergistically enhance immune cells’ ability to mount a response against cancer cells. In addition, we are working to identify mechanisms by which tumours evade immune systems and target weak points in the cancer immunity cycle.
Molecularly Targeted Agents: The ability to identify specific disease subpopulations through mutations in certain genes and proteins is a critical advancement in oncology, making possible new treatments that are more effective than ever. Rational drug design, in which targets are selected based on their observed role in cancer cell growth and survival, has been a mainstay of our development efforts in specific disease subpopulations from the start.
Combination Solutions: BeiGene is evaluating combination therapies that target distinct steps of anti-tumour immunity, exploring synergies that could result in stronger and more sustained responses.
Pipeline Information
Learn about clinical-stage development programs in solid tumours and haematology and view mechanism of action videos.
Pipeline Resource
Download the pipeline resource for an overview of BeiGene’s investigational compounds and combinations in our solid tumour oncology and haematology disease areas of interest.
ESMO Industry Sponsored Satellite Symposia
ESMO Congress 2024
Experts: Tony S.K. Mok (Hong Kong), Martin Reck (Germany)
Advances in upper GI immunotherapy: What’s new on the horizon?
Experts: Sylvie Lorenzen (Germany), Filippo Pietrantonio (Italy), Jean-Philippe Metges (France), Matteo Fassan (Italy) and Maria Alsina Maqueda (Spain)
ESMO Congress 2022
Standard of Care is Not Enough! Talking Immunotherapy Clinical Trials in GI Cancers
Experts: Elizabeth Smyth (United Kingdom), Eric Van Cutsem (Belgium), Michel Ducreux (France), Sylvie Lorenzen (Germany), and Lesley Fallowfield (United Kingdom)
ESMO Congress 2021
Experts: Heather A. Wakelee (USA), Benjamin Besse (France), Stephen V. Liu (USA), Riyaz Shah (United Kingdom), and Ross Soo (Singapore)
ESMO Virtual Congress 2020
PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
Experts: Tony Mok (Hong Kong), Giorgio Scagliotti (Italy), Anne-Marie C. Dingemans (Netherlands), and Raffaele Califano (United Kingdom)
ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.